Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats

Background: Prostaglandins are implicated in periodontal bone destruction. We investigated the effect of a non-selective cyclooxygenase (COX) inhibito r (indomethacin-IND) or a type 2 COX inhibitor (meloxicam-MLX) in an experi mental periodontal disease (EPD) model. Methods: Wistar rats were subjected to placement of a nylon thread ligature around the maxillary molars and sacrificed after 7 days. Alveolar bone los s (ABL) was measured in one quadrant as the distance between the cemento-en amel junction and the alveolar bone. The other quadrant was processed for h istopathologic analysis. Daily weight and white blood cell count were recor ded. Groups were treated subcutaneously for 7 days with either IND (0.5, 1, or 2 mg/kg) or MXL (0.75, 1.5, or 3 mg/kg). Controls received no treatment . Macroscopic analysis of the gastric mucosa was done. The control group di d not receive any manipulation, and a non-treated group consisted of rats s ubjected to periodontitis that received no pharmacological treatment. Results: In the non-treated (NT) group, there was significant ABL, severe m ononuclear influx, and an increase in osteoclast numbers. Significant neutr ophilia and lymphomonocytosis occurred at 6 hours and at 7 days, respective ly, as compared to controls. Significant weight loss persisted until the se venth day in the NT group. Both IND and MXL reduced ABL and histopathologic changes. Neutrophilia and lymphomonocytosis were also significantly revers ed. Both IND and MLX induced earlier weight recovery. The stomachs of the I ND (1 and 2 mg/kg) groups presented hemorrhage and ulcers, whereas in the M LX-treated groups, there were mild petechiae just in the 3 mg/kg group. Conclusions: COX inhibition prevented ABL in this experimental periodontal disease model. MXL displays similar efficacy and less gastric damage than I ND. MXL may provide a better risk/benefit ratio in the treatment of human p eriodontitis than non-selective COX inhibitors.